New developments and technologies in hereditary cancer

Results of the CREATE-X trial

Hormonal treatments produce similar quality of life outcomes in DCIS

No significant difference in recurrence rates among women with DCIS taking anastrozole or tamoxifen

Treating women with endocrine-resistant HR /HER2 advanced breast cancer

No significant difference in recurrence rates among women with DCIS taking anastrozole or tamoxifen

Patients with DCIS receiving anastrozole reported symptoms different from those receiving tamoxifen both groups reported similar quality of life

Estrogen receptor mutations detected in plasma associated with worse overall survival in metastatic breast cancer

Improved survival outcomes in women with HER2-negative breast cancer after neoadjuvant chemotherapy

Breast-conserving therapy yields better 10-year outcomes than mastectomy for early-stage patients

Adding carboplatin to presurgery chemotherapy improved disease-free survival for patients with triple-negative breast cancer

Analysis of blood samples finds ESR1 gene mutations are prevalent and associated with worse overall survival